Efficacy of Erythropoietin to Prevent Acute Kidney Injury in Chronic Kidney Disease Patients Undergoing Cardiac Surgery

• Status: Unknown status
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to demonstrate the efficacy of erythropoietin for prevention acute kidney injury in CKD patients undergoing cardiac surgery.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Thammasat University
• Treatments: Epoetin Alfa

Criteria

Inclusion Criteria:

• age > 18 years.

• serum creatinine levels > 1.2 mg/dL and baseline creatinine clearance levels < 60 mL/min (as measured in their most recent sample,drawn within 2 months prior to the beginning of the study)

• patients who need cardiac surgery

Exclusion Criteria:

• patients with acute kidney injury

• end stage renal disease (requiring dialysis)

• unstable renal function (as evidenced by a change in serum creatinine of > 0.5 mg/dL, or > 25%, within 14 days prior to the study)

• allergy to any of erythropoietin

• suffered from congestive heart failure, cardiogenic shock or emergent cardiac surgery.

• receiving erythropoietin within 14 days before the study